Medicare Finalizes Drug Price Negotiation Rules For 2029 And Beyond, With A New Check On Reformulated Drugs

The rule takes effect Dec. 5, 2026, and covers up to 20 drugs per cycle starting with initial price applicability year 2029.

Share
Medicare Finalizes Drug Price Negotiation Rules For 2029 And Beyond, With A New Check On Reformulated Drugs

The Centers for Medicare & Medicaid Services (CMS), the federal agency that runs Medicare, finalized a rule on Thursday that writes its drug price negotiation program into permanent regulation for 2029 and beyond. It also closes what the agency calls a program integrity risk: a manufacturer dodging selection or a negotiated price by launching a reformulated version of a drug.

From guidance to regulation

For the first three cycles, covering initial price applicability years 2026 through 2028, statute directed CMS to run the program through program instruction and other guidance. CMS said that authority is expiring, so the final rule (CMS-4215-F) codifies the policies for 2029 onward. It takes effect Dec. 5, 2026.

The program comes from sections 11001 and 11002 of the Inflation Reduction Act of 2022. It sets up negotiation of maximum fair prices for certain high-expenditure, single-source drugs and biological products.

For 2029 and each later year, CMS will select up to 20 drugs covered under Part D and/or payable under Part B. It may also pick drugs for renegotiation if ones with an agreed price meet eligibility and selection criteria.

CMS said the rule builds on the first three cycles' policies, adds new requirements for the fourth and later cycles, and puts a particular focus on transparency. It also revises or clarifies some earlier policies based on lessons learned.

The fixed-combination loophole

The sharpest change targets fixed combination drugs, those with two or more active ingredients. Under the 2026-2028 policy, CMS said, a manufacturer could avoid selection, or avoid the negotiated price on a drug already selected, by marketing a new formulation that adds an ingredient and enables a different route of administration for the original ingredient.

CMS said that outcome would sit in tension with the statutory requirement to identify qualifying single-source drugs by aggregating across dosage forms and strengths, including new formulations. It finalized its proposed policy on specific fixed combination drugs to address the risk.

CMS also clarified how withdrawn approvals for indications are treated when judging whether a drug that formerly qualified for the orphan drug exclusion is still eligible, following amendments in the "Working Families Tax Cut" legislation.

Manufacturer duties and deselection

A willing primary manufacturer must sign the Negotiation Program Agreement by Feb. 28 after the selected drug publication date, the agency said. The agreement stays in force, including through renegotiation, until the drug stops being a selected drug because a generic is approved or a biosimilar is licensed and is subject to Bona Fide Marketing, unless the manufacturer terminates sooner under specified conditions.

CMS finalized details on how a primary manufacturer can transfer responsibility under the agreement to another entity. It also codified the process and timing for deciding a drug is ineligible or deselected, and for monitoring that generics or biosimilars continue to be marketed.

For renegotiation of 2029 and later, CMS will weigh a drug's agreed price as part of the statutory factors it considers.

The rule takes effect Dec. 5, 2026, ahead of the fourth negotiation cycle, which covers initial price applicability year 2029.

Sources